Ocugen to Present at Investing in Cures Summit
March 06 2024 - 7:30AM
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines,
announced that Dr. Shankar Musunuri, Chairman, Chief Executive
Officer and Co-Founder of Ocugen will be a panelist at the
Investing in Cures Summit 2024 from March 8-9, 2024 at the Fairmont
Scottsdale Princess Hotel in Scottsdale, AZ.
“I look forward to joining my peers in discussing therapeutic
approaches to treat inherited retinal diseases that can help slow
or reverse degeneration regardless of the underlying genetic
cause,” said Dr. Musunuri. “Ocugen’s modifier gene therapy platform
can potentially address multiple genetic defects with a single
product utilizing a gene agnostic approach that restores
homeostasis in the retina.”
The Investing in Cures Summit includes presentations by the
world’s leading industry, clinical and retinal science innovators
and is hosted by the Foundation Fighting Blindness and the RD
Fund.
Details for the panel are as follows:
Event: Investing in Cures Summit 2024—Global
Community
Topic: Gene Agnostics: Broad Spectrum
Therapeutic Strategies to Address Retinal Disease
Time: 2:45-3:20 p.m. MT
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, and vaccines that
improve health and offer hope for patients across the globe. We are
making an impact on patients’ lives through courageous
innovation—forging new scientific paths that harness our unique
intellectual and human capital. Our breakthrough modifier gene
therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, which are
subject to risks and uncertainties. We may, in some cases, use
terms such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” or other
words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Such statements are
subject to numerous important factors, risks, and uncertainties
that may cause actual events or results to differ materially from
our current expectations. These and other risks and uncertainties
are more fully described in our periodic filings with the
Securities and Exchange Commission (SEC), including the risk
factors described in the section entitled “Risk Factors” in the
quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events, or otherwise, after the date of this
press release.
Contact:Tiffany HamiltonHead of
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024